{"schema_version":"secwatch.filing_event.v1","accession":"0001370053-24-000067","form_type":"8-K","ticker":"ANAB","cik":"0001370053","company_name":"ANAPTYSBIO, INC","filed_at":"2024-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.272767+00:00","generated_at":"2026-05-29T04:40:06.924239+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"AnaptysBio Phase 2B trial of ANB032 fails endpoints in atopic dermatitis; cash ~$415M","bullets":["ANB032 did not meet primary endpoint EASI-75 or any secondary endpoints at Week 14 in 201-patient ARISE-AD trial.","Higher placebo rates than historical norms, particularly in U.S., contributed to failure; drug well tolerated with no safety signals.","Cash, equivalents and investments expected to be ~$415M at Dec 31, 2024, funding operations through year-end 2027.","One serious adverse event (worsening AD) across active arms; no dose relationship or imbalance in adverse events."],"urls":{"canonical":"https://secwatch.observer/filing/0001370053-24-000067","json":"https://secwatch.observer/filing/0001370053-24-000067.json","markdown":"https://secwatch.observer/filing/0001370053-24-000067.md","text":"https://secwatch.observer/filing/0001370053-24-000067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370053/000137005324000067/0001370053-24-000067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370053/000137005324000067/anab-20241211.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T04:40:06.924239+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}